By Chris Wack
Anaptys said Monday that it saw positive top-line results from its global Phase 3 trial evaluating the safety and efficacy of imsidolimab in patients with generalized pustular psoriasis flares.
The stock was halted at $19.25 in premarket trading.
The biotechnology company said that investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling after a single dose of 750mg IV imsidolimab.
Top-line data also demonstrate a favorable safety and tolerability profile.
All adverse effects reported in imsidolimab-treated patients were mild or moderate and balanced across imsidolimab-treated versus placebo patients. No serious or severe adverse effects were reported in imsidolimab-treated patients.
Anaptys plans to present comprehensive data from the trial in the second half of 2024. The company anticipates filing a biologics license application with the U.S. Food and Drug Administration by the third quarter of 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
10-09-23 0828ET